[1]
|
Sterns, R.H. (2015) Disorders of Plasma Sodium—Causes, Consequences, and Correction. The New England Journal of Medicine, 372, 55-65. https://doi.org/10.1056/NEJMra1404489
|
[2]
|
Raspotnig, M., Vedeler, C. and Storstein, A. (2015) Paraneoplastic Neurological Syndromes in Lung Cancer Patients with or without Onconeural Antibodies. Journal of the Neurological Sciences, 348, 41-45.
https://doi.org/10.1016/j.jns.2014.10.040
|
[3]
|
Humayun, M.A. and Cranston, I.C. (2017) In-Patient Tolvaptan Use in SIADH: Care Audit, Therapy Observation and Outcome Analysis. BMC Endocrine Disorders, 17, Article No. 69. https://doi.org/10.1186/s12902-017-0214-2
|
[4]
|
Marroncini, G., et al. (2021) Low Sodium and Tolvaptan Have Opposite Effects in Human Small Cell Lung Cancer Cells. Molecular and Cellular Endocrinology, 537, Article ID: 111419. https://doi.org/10.1016/j.mce.2021.111419
|
[5]
|
Schrier, R.W., et al. (2006) Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. The New England Journal of Medicine, 355, 2099-2112. https://doi.org/10.1056/NEJMoa065181
|
[6]
|
Martin, R.J. (2004) Central Pontine and Extrapontine Myelinolysis: The Osmotic Demyelination Syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 75, iii22-iii28. https://doi.org/10.1136/jnnp.2004.045906
|
[7]
|
Adrogue, H.J. and Madias, N.E. (2000) Hyponatremia. The New England Journal of Medicine, 342, 1581-1589.
https://doi.org/10.1056/NEJM200005253422107
|
[8]
|
Georgy, V., Mullhi, D. and Jones, A.F. (2007) Central Pon-tine Myelinolysis Following “Optimal” Rate of Correction of Hyponatraemia with a Good Clinical Outcome. Annals of Clinical Biochemistry, 44, 488-490.
https://doi.org/10.1258/000456307781646067
|
[9]
|
Kleinschmidt-Demasters, B.K., Rojiani, A.M. and Filley, C.M. (2006) Central and Extrapontine Myelinolysis: Then ... and Now. Journal of Neuropathology & Experimental Neurology, 65, 1-11.
https://doi.org/10.1097/01.jnen.0000196131.72302.68
|
[10]
|
Chang, Y., An, D.-H., Xing, Y. and Qi, X. (2012) Central Pontine and Extrapontine Myelinolysis Associated with Acute Hepatic Dysfunction. Neurological Sciences, 33, 673-676. https://doi.org/10.1007/s10072-011-0838-3
|
[11]
|
Lampl, C. and Yazdi, K. (2002) Central Pontine Mye-linolysis. European Neurology, 47, 3-10.
https://doi.org/10.1159/000047939
|
[12]
|
Burcar, P.J., Norenberg, M.D. and Yarnell, P.R. (1977) Hyponatremia and Central Pontine Myelinolysis. Neurology, 27, 223-226. https://doi.org/10.1212/WNL.27.3.223
|
[13]
|
Lambeck, J., Hieber, M., Dreßing, A. and Niesen, W.D. (2019) Central Pontine Myelinosis and Osmotic Demyelination Syndrome. Deutsches Ärzteblatt International, 116, 600-606. https://doi.org/10.3238/arztebl.2019.0600
|
[14]
|
Forster, A., et al. (2013) Value of Diffusion-Weighted Imaging in Central Pontine and Extrapontine Myelinolysis. Neuroradiology, 55, 49-56. https://doi.org/10.1007/s00234-012-1083-z
|
[15]
|
Chua, G.C., Sitoh, Y.Y., Lim, C.C., Chua, H.C. and Ng, P.Y. (2002) MRI Findings in Osmotic Myelinolysis. Clinical Radiology, 57, 800-806. https://doi.org/10.1053/crad.2002.0977
|
[16]
|
Takagi, H., et al. (2014) Minocycline Prevents Osmotic Demyelination Associated with Aquaresis. Kidney International, 86, 954-964. https://doi.org/10.1038/ki.2014.119
|
[17]
|
Berl, T., et al. (2010) Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia. Journal of the American Society of Nephrology, 21, 705-712. https://doi.org/10.1681/ASN.2009080857
|
[18]
|
Doggrell, S.A. (2004) Tolvaptan (Otsuka). Current Opinion in Investigational Drugs, 5, 977-983.
|
[19]
|
Ren, P. and Yang, Q. (2021) The Role of Tolvaptan in Managing Hyponatremia in Small Cell Lung Cancer Patients with SIADH: A Retrospective Study of 23 Cases. Translational Can-cer Research, 10, 1229-1237.
https://doi.org/10.21037/tcr-20-2123
|
[20]
|
Shoaf, S.E., Bricmont, P. and Dandurand, A. (2017) Low-Dose Tolvaptan PK/PD: Comparison of Patients with Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion to Healthy Adults. European Journal of Clinical Pharmacology, 73, 1399-1408. https://doi.org/10.1007/s00228-017-2302-7
|
[21]
|
Kim, Y., Lee, N., Lee, K.E. and Gwak, H.S. (2020) Risk Factors for Sodium Overcorrection in Non-Hypovolemic Hyponatremia Patients Treated with Tolvaptan. European Journal of Clinical Pharmacology, 76, 723-729.
https://doi.org/10.1007/s00228-020-02848-6
|
[22]
|
Kleindienst, A., et al. (2020) Tolvaptan versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery. Journal of the Endocrine Society, 4, bvaa068.
https://doi.org/10.1210/jendso/bvaa068
|
[23]
|
Zmily, H.D., Daifallah, S. and Ghali, J.K. (2011) Tolvaptan, Hypo-natremia, and Heart Failure. International Journal of Nephrology and Renovascular Disease, 4, 57-71. https://doi.org/10.2147/IJNRD.S7032
|